Short Communication VAP Angioimmunoblastic Lymphadenopathy

Cancer Chemotherapy and Pharmacology

, Volume 10, Issue 3, pp 221-222

First online:

Therapeutic effect of vincristine, adriamycin and prednisolone (VAP) in angioimmunoblastic lymphadenopathy (AIL)

  • Abdallah S. AwidiAffiliated withDepartment of Internal Medicine, Jordan University Hospital
  • , Musleh S. TarawnehAffiliated withDepartment of Pathology, Jordan University Hospital
  • , Mahmoud S. Abu KhalafAffiliated withDepartment of Surgery, Jordan University Hospital
  • , Mohammad S. Al KhateebAffiliated withDepartment of Microbiology, Jordan University Hospital
  • , Samir S. AmrAffiliated withDepartment of Pathology, Jordan University Hospital

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Five patients, three males and two females, with angioimmunoblastic lymphadenopathy (AIL) are described. The two who received steroids had no response and died 2 and 6 months later. The three patients who received vincristine, adriamycin and prednisolone (VAP) went into remission early and are still in remission with a follow-up of 22–35 months. It is concluded that VAP is effective therapy in AIL.